DIR Return Create A Forum - Home
       ---------------------------------------------------------
       MS Speaks
  HTML https://msspeaks.createaforum.com
       ---------------------------------------------------------
       *****************************************************
   DIR Return to: OCREVUS (ocrelizumab)
       *****************************************************
       #Post#: 4186--------------------------------------------------
       (ECTRIMS) Ocrevus benefit confirmed in patients over 60 with MS
   DIR By: agate
       Date: October 14, 2023, 12:41 am
       ---------------------------------------------------------
       From MedPage Today (October 12, 2023)--"Ocrelizumab benefit
       confirmed in older patients with MS"--a report from the ECTRIMS
       conference (October 2023). Please note that the article runs for
       3 pages.
  HTML https://www.medscape.com/viewarticle/997332?form=fpf
       Excerpt:
       --- Quote ---
       >
       >
       >
       > The researchers studied about 700 patients with multiple
       sclerosis aged 60 years and older from an international
       database, comparing outcomes with the anti-CD20 monoclonal
       antibody ocrelizumab vs those for interferon/ glatiramer acetate
       (BRACE). They found ocrelizumab significantly reduced the annual
       rate of relapses, although after adjustments, patients overall
       faced a relapse rate of less than 0.1 per year. There were also
       no significant differences in either disability progression or
       improvement between the two treatments.
       --- End Quote ---
       *****************************************************
       Page 1 of 1